SrasV1, Main, Exploration, bibRecord, 002F22

New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CLpro inhibitors

Identifieur interne : 002F22 ( Main/Exploration ); précédent : 002F21; suivant : 002F23

New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CLpro inhibitors

Auteurs : Thomas Regnier [Japon] ; Diganta Sarma [Japon] ; Koushi Hidaka [Japon] ; Usman Bacha [États-Unis] ; Ernesto Freire [États-Unis] ; Yoshio Hayashi [Japon] ; Yoshiaki Kiso [Japon]

Source :

Bioorganic & medicinal chemistry letters : (Print) [ 0960-894X ] ; 2009.

RBID : Pascal:09-0329242

Descripteurs français

Pascal (Inist)
- Synthèse chimique, Activité biologique, Antiviral, Virus syndrome respiratoire aigu sévère, Inhibiteur protease, Cysteine endopeptidases, Dipeptide, In vitro, Méthode dynamique moléculaire, Dérivé du thiazole, Dérivé de la pyrrolidinone, Valine dérivé, Fluor Composé organique, Inhibiteur enzyme, Modélisation, Peptide, Leucinamide(benzyloxycarbonylvalyl-N-[2-(2-oxopyrrolidin-3-yl)-1-(thiazol-2-ylcarbonyl)éthyl]), Leucine dérivé.

English descriptors

KwdEn :
- Antiviral, Biological activity, Chemical synthesis, Cysteine endopeptidases, Dipeptides, Enzyme inhibitor, Fluorine Organic compounds, In vitro, Modeling, Molecular dynamics method, Peptides, Protease inhibitor, Pyrrolidone derivatives, Severe acute respiratory syndrome virus, Thiazole derivatives, Valine derivatives.

Abstract

A series of trifluoromethyl, benzothiazolyl or thiazolyl ketone-containing peptidic compounds as SARS-CoV 3CL protease inhibitors were developed and their potency was evaluated by in vitro protease inhibitory assays. Three candidates had encouraging results for the development of new anti-SARS compounds.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000199
to stream PascalFrancis, to step Curation: 000789
to stream PascalFrancis, to step Checkpoint: 000201
to stream Main, to step Merge: 002F78
to stream Main, to step Curation: 002F22

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL<sup>pro</sup>
 inhibitors</title>
<author><name sortKey="Regnier, Thomas" sort="Regnier, Thomas" uniqKey="Regnier T" first="Thomas" last="Regnier">Thomas Regnier</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicinal Chemistry, Center for Frontier Research in Medicinal Science, 21st Century COE Program, Kyoto Pharmaceutical University</s1>
<s2>Kyoto 607-8412</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Kyoto 607-8412</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sarma, Diganta" sort="Sarma, Diganta" uniqKey="Sarma D" first="Diganta" last="Sarma">Diganta Sarma</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicinal Chemistry, Center for Frontier Research in Medicinal Science, 21st Century COE Program, Kyoto Pharmaceutical University</s1>
<s2>Kyoto 607-8412</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Kyoto 607-8412</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hidaka, Koushi" sort="Hidaka, Koushi" uniqKey="Hidaka K" first="Koushi" last="Hidaka">Koushi Hidaka</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicinal Chemistry, Center for Frontier Research in Medicinal Science, 21st Century COE Program, Kyoto Pharmaceutical University</s1>
<s2>Kyoto 607-8412</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Kyoto 607-8412</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bacha, Usman" sort="Bacha, Usman" uniqKey="Bacha U" first="Usman" last="Bacha">Usman Bacha</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Biology, Johns Hopkins University</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Freire, Ernesto" sort="Freire, Ernesto" uniqKey="Freire E" first="Ernesto" last="Freire">Ernesto Freire</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Biology, Johns Hopkins University</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hayashi, Yoshio" sort="Hayashi, Yoshio" uniqKey="Hayashi Y" first="Yoshio" last="Hayashi">Yoshio Hayashi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicinal Chemistry, Center for Frontier Research in Medicinal Science, 21st Century COE Program, Kyoto Pharmaceutical University</s1>
<s2>Kyoto 607-8412</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Kyoto 607-8412</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Medicinal Chemistry, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences</s1>
<s2>Tokyo 192-0392</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kiso, Yoshiaki" sort="Kiso, Yoshiaki" uniqKey="Kiso Y" first="Yoshiaki" last="Kiso">Yoshiaki Kiso</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicinal Chemistry, Center for Frontier Research in Medicinal Science, 21st Century COE Program, Kyoto Pharmaceutical University</s1>
<s2>Kyoto 607-8412</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Kyoto 607-8412</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0329242</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0329242 INIST</idno>
<idno type="RBID">Pascal:09-0329242</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000199</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000789</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000201</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000201</idno>
<idno type="wicri:doubleKey">0960-894X:2009:Regnier T:new:developments:for</idno>
<idno type="wicri:Area/Main/Merge">002F78</idno>
<idno type="wicri:Area/Main/Curation">002F22</idno>
<idno type="wicri:Area/Main/Exploration">002F22</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL<sup>pro</sup>
 inhibitors</title>
<author><name sortKey="Regnier, Thomas" sort="Regnier, Thomas" uniqKey="Regnier T" first="Thomas" last="Regnier">Thomas Regnier</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicinal Chemistry, Center for Frontier Research in Medicinal Science, 21st Century COE Program, Kyoto Pharmaceutical University</s1>
<s2>Kyoto 607-8412</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Kyoto 607-8412</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sarma, Diganta" sort="Sarma, Diganta" uniqKey="Sarma D" first="Diganta" last="Sarma">Diganta Sarma</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicinal Chemistry, Center for Frontier Research in Medicinal Science, 21st Century COE Program, Kyoto Pharmaceutical University</s1>
<s2>Kyoto 607-8412</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Kyoto 607-8412</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hidaka, Koushi" sort="Hidaka, Koushi" uniqKey="Hidaka K" first="Koushi" last="Hidaka">Koushi Hidaka</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicinal Chemistry, Center for Frontier Research in Medicinal Science, 21st Century COE Program, Kyoto Pharmaceutical University</s1>
<s2>Kyoto 607-8412</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Kyoto 607-8412</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bacha, Usman" sort="Bacha, Usman" uniqKey="Bacha U" first="Usman" last="Bacha">Usman Bacha</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Biology, Johns Hopkins University</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Freire, Ernesto" sort="Freire, Ernesto" uniqKey="Freire E" first="Ernesto" last="Freire">Ernesto Freire</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Biology, Johns Hopkins University</s1>
<s2>Baltimore, MD</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hayashi, Yoshio" sort="Hayashi, Yoshio" uniqKey="Hayashi Y" first="Yoshio" last="Hayashi">Yoshio Hayashi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicinal Chemistry, Center for Frontier Research in Medicinal Science, 21st Century COE Program, Kyoto Pharmaceutical University</s1>
<s2>Kyoto 607-8412</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Kyoto 607-8412</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Medicinal Chemistry, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences</s1>
<s2>Tokyo 192-0392</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kiso, Yoshiaki" sort="Kiso, Yoshiaki" uniqKey="Kiso Y" first="Yoshiaki" last="Kiso">Yoshiaki Kiso</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicinal Chemistry, Center for Frontier Research in Medicinal Science, 21st Century COE Program, Kyoto Pharmaceutical University</s1>
<s2>Kyoto 607-8412</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Kyoto 607-8412</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Bioorganic & medicinal chemistry letters : (Print)</title>
<title level="j" type="abbreviated">Bioorg. med. chem. lett. : (Print)</title>
<idno type="ISSN">0960-894X</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Bioorganic & medicinal chemistry letters : (Print)</title>
<title level="j" type="abbreviated">Bioorg. med. chem. lett. : (Print)</title>
<idno type="ISSN">0960-894X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term>
<term>Biological activity</term>
<term>Chemical synthesis</term>
<term>Cysteine endopeptidases</term>
<term>Dipeptides</term>
<term>Enzyme inhibitor</term>
<term>Fluorine Organic compounds</term>
<term>In vitro</term>
<term>Modeling</term>
<term>Molecular dynamics method</term>
<term>Peptides</term>
<term>Protease inhibitor</term>
<term>Pyrrolidone derivatives</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Thiazole derivatives</term>
<term>Valine derivatives</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Synthèse chimique</term>
<term>Activité biologique</term>
<term>Antiviral</term>
<term>Virus syndrome respiratoire aigu sévère</term>
<term>Inhibiteur protease</term>
<term>Cysteine endopeptidases</term>
<term>Dipeptide</term>
<term>In vitro</term>
<term>Méthode dynamique moléculaire</term>
<term>Dérivé du thiazole</term>
<term>Dérivé de la pyrrolidinone</term>
<term>Valine dérivé</term>
<term>Fluor Composé organique</term>
<term>Inhibiteur enzyme</term>
<term>Modélisation</term>
<term>Peptide</term>
<term>Leucinamide(benzyloxycarbonylvalyl-N-[2-(2-oxopyrrolidin-3-yl)-1-(thiazol-2-ylcarbonyl)éthyl])</term>
<term>Leucine dérivé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A series of trifluoromethyl, benzothiazolyl or thiazolyl ketone-containing peptidic compounds as SARS-CoV 3CL protease inhibitors were developed and their potency was evaluated by in vitro protease inhibitory assays. Three candidates had encouraging results for the development of new anti-SARS compounds.</div>
</front>
</TEI>
<affiliations><list><country><li>Japon</li>
<li>États-Unis</li>
</country>
<region><li>Maryland</li>
<li>Région de Kantō</li>
</region>
<settlement><li>Tokyo</li>
</settlement>
</list>
<tree><country name="Japon"><noRegion><name sortKey="Regnier, Thomas" sort="Regnier, Thomas" uniqKey="Regnier T" first="Thomas" last="Regnier">Thomas Regnier</name>
</noRegion>
<name sortKey="Hayashi, Yoshio" sort="Hayashi, Yoshio" uniqKey="Hayashi Y" first="Yoshio" last="Hayashi">Yoshio Hayashi</name>
<name sortKey="Hayashi, Yoshio" sort="Hayashi, Yoshio" uniqKey="Hayashi Y" first="Yoshio" last="Hayashi">Yoshio Hayashi</name>
<name sortKey="Hidaka, Koushi" sort="Hidaka, Koushi" uniqKey="Hidaka K" first="Koushi" last="Hidaka">Koushi Hidaka</name>
<name sortKey="Kiso, Yoshiaki" sort="Kiso, Yoshiaki" uniqKey="Kiso Y" first="Yoshiaki" last="Kiso">Yoshiaki Kiso</name>
<name sortKey="Sarma, Diganta" sort="Sarma, Diganta" uniqKey="Sarma D" first="Diganta" last="Sarma">Diganta Sarma</name>
</country>
<country name="États-Unis"><region name="Maryland"><name sortKey="Bacha, Usman" sort="Bacha, Usman" uniqKey="Bacha U" first="Usman" last="Bacha">Usman Bacha</name>
</region>
<name sortKey="Freire, Ernesto" sort="Freire, Ernesto" uniqKey="Freire E" first="Ernesto" last="Freire">Ernesto Freire</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F22 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002F22 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:09-0329242
   |texte=   New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CLpro inhibitors
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CLpro inhibitors

New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CLpro inhibitors

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri